|1.||Carolei, Antonio: 4 articles (07/2013 - 01/2009)|
|2.||Sacco, Simona: 4 articles (07/2013 - 01/2009)|
|3.||Toni, Danilo: 3 articles (01/2012 - 01/2009)|
|4.||Zaninelli, Augusto: 3 articles (01/2012 - 01/2009)|
|5.||Stocchi, Fabrizio: 2 articles (01/2015 - 07/2010)|
|6.||Marconi, Stefano: 2 articles (01/2015 - 07/2010)|
|7.||Cimminiello, Claudio: 2 articles (01/2012 - 01/2009)|
|8.||Gensini, Gian Franco: 2 articles (07/2011 - 01/2009)|
|9.||Bignamini, Angelo A: 2 articles (07/2011 - 01/2009)|
|10.||Dal Negro, R W: 2 articles (01/2008 - 12/2007)|
07/01/2013 - "The database of the SIRIO study (a large observational study of 2,573 patients with stroke admitted in Italian hospitals in 2005) was used to identify an mRS threshold to define MS. Reference was made to outcome markers such as rate of discharge to home, 1-year disability and 1-year mortality. "
01/01/2012 - "SIRIO was a multicenter observational study enrolling patients during the acute phase of stroke of both ischemic and hemorrhagic origin. "
01/01/2012 - "This post hoc analysis of the findings of the SIRIO trial (Stroke in Italy and Related Impact on Outcome) examined the prognostic impact of systemic atherothrombosis. "
01/01/2012 - "Atherothrombotic burden and medium-term prognosis in patients with acute ischemic stroke: findings of the SIRIO study."
07/01/2011 - "Stroke in Italy and Related Impact on Outcome (SIRIO) was a prospective, nationwide, multicenter, hospital-based, observational study that included patients aged.18 years with acute ischemic stroke. "
|2.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2015 - "A first estimate of the economic burden of COPD in Italy was conducted in 2008 (the SIRIO [Social Impact of Respiratory Integrated Outcomes] study). "
01/01/2008 - "The aim of the Social Impact of Respiratory Integrated Outcomes (SIRIO) study was to measure the health resources consumption and costs generated in 1 year by a population of patients with chronic obstructive pulmonary disease (COPD) in a real-life setting. "
01/01/2008 - "Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes)."
|3.||Asthma (Bronchial Asthma)
|4.||Parkinson Disease (Parkinson's Disease)
07/01/2010 - "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)."
01/01/2015 - "To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating Parkinson's disease. "
07/01/2010 - "This review evaluates some of the pharmacologic strategies in the management of motor complications in Parkinson disease and therapy optimization, with a focus on the use of CHF 1512 (Sirio), a combination of melevodopa (l-dopa methylester, a highly soluble prodrug of l-dopa) plus carbidopa in an effervescent tablet formulation."
|1.||Levodopa (L Dopa)
|3.||levodopa methyl ester